Previous Article | Next Article 
Journal of Virology, June 1999, p. 4590-4599, Vol. 73, No. 6
0022-538X/99/$04.00+0
Vaccinia Virus WR Gene A5L Is Required for
Morphogenesis of Mature Virions
Ollie
Williams,1
Elizabeth J.
Wolffe,2
Andrea S.
Weisberg,2 and
Michael
Merchlinsky1,*
Laboratory of Viral Diseases, Center for
Biologics Evaluation and Research, Food and Drug Administration,
Rockville, Maryland 20852,1 and
Laboratory of Viral Diseases, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, Bethesda,
Maryland 208922
Received 19 November 1998/Accepted 8 March 1999
 |
ABSTRACT |
The vaccinia virus WR A5L open reading frame (corresponding to open
reading frame A4L in vaccinia virus Copenhagen) encodes an
immunodominant late protein found in the core of the vaccinia virion.
To investigate the role of this protein in vaccinia virus replication,
we have constructed a recombinant virus, vA5Li, in which the endogenous
gene has been deleted and an inducible copy of the A5 gene dependent on
isopropyl-
-D-thiogalactopyranoside (IPTG) for expression
has been inserted into the genome. In the absence of inducer, the yield
of infectious virus was dramatically reduced. However, DNA synthesis
and processing, viral protein expression (except for A5), and early
stages in virion formation were indistinguishable from the analogous
steps in a normal infection. Electron microscopy revealed that the
major vaccinia virus structural form present in cells infected with
vA5Li in the absence of inducer was immature virions. Viral particles
were purified from vA5Li-infected cells in the presence and absence of
inducer. Both particles contained viral DNA and the full complement of
viral proteins, except for A5, which was missing from particles
prepared in the absence of inducer. The particles prepared in the
presence of IPTG were more infectious than those prepared in its
absence. The A5 protein appears to be required for the immature virion
to form the brick-shaped intracellular mature virion.
 |
INTRODUCTION |
Vaccinia virus, the archetypal
member of the poxvirus family, is a large DNA virus which encodes
approximately 185 proteins (30). The cascade of temporally
related gene expression, the replication of the genome, and the
assembly and maturation of the infectious virion all occur in the
cytoplasm of the infected cell. The earliest observed specific
structures generated via infection were regions of granular
electron-dense material, or viral factories, enriched in vaccinia virus
DNA, which are thought to be the site of viral DNA replication and
transcription (4, 18, 21, 30). The initial step in virion
morphogenesis is the accumulation of crescent-shaped membranes at the
cytoplasmic sites of viral replication (7). These membranes
encircle the granular electron-dense material to form spherical
immature virion (IV) particles. The spherical IV particles develop an
internal core surrounding the DNA and mature into brick-shaped
intracellular mature virion (IMV) particles. This maturation coincides
with the cleavage of several core proteins (24, 25, 32, 44, 48-50). Three basic approaches have been used to delineate the molecular details of vaccinia virus morphogenesis: the characterization of temperature-sensitive mutants with defects in assembly, the use of
drugs which inhibit the process and the characterization of mutant
viruses resistant to such drugs, and the construction of
inducer-dependent conditional mutants in which the expression of a
specified gene can be controlled. By using these approaches, proteins
directly or indirectly involved in the early stages of morphogenesis
(36, 37, 46, 47, 51, 54, 55), in the transition from IV to
IMV particles (5, 13, 22, 35, 57), and in the process
leading to the formation of extracellular enveloped virus (3, 9,
12, 34, 38, 39, 42, 53) have been identified.
A vaccinia virus protein, designated p39, was shown to be expressed
late in infection, to elicit a strong persistent antigenic response in
humans, and to correspond to the product of the A4L gene in vaccinia
virus Copenhagen or A5L in vaccinia virus WR (8, 27). The
protein can be detected in the virosomes, the regions of DNA
replication, and becomes encapsidated in the virion core during
maturation as shown by immunolabeling and electron microscopy
(6). Vaccinia virions contain a nuclease activity (15,
26, 28, 40, 41) which was shown to copurify with the A5 protein
over chromatographic columns (29a). The colocalization of A5
with replicated DNA in the virosomes and its copurification with
nuclease activity suggested a possible role for A5 during DNA
processing or packaging. To determine the role A5 plays in the
replication of vaccinia virus, we have taken an in vivo genetic approach by constructing and characterizing a conditional lethal mutant
of vaccinia virus with an inducible A5L gene.
 |
MATERIALS AND METHODS |
Cells and viruses.
BSC-1 cells (ATCC CCL6) were grown in
Eagle's minimal essential medium (Gibco or Cellgro) supplemented with
10% fetal bovine serum (HyClone). Wild-type and recombinant vaccinia
viruses were derived from the WR strain (ATCC Vr119). To prepare stocks
of vA5Li, monolayers of BSC-1 cells were infected with 1 PFU/cell in
the presence of 50 µM
isopropyl-
-D-thiogalactopyranoside (IPTG). Cells were
harvested 72 h postinfection, and virus stocks were prepared by
three freeze-thaw cycles. Partially purified virus, prepared by
centrifugation of infected cytoplasm through a 36% sucrose cushion
(11), was routinely used to infect cells for experiments.
Plasmid construction.
A copy of the A5L open reading frame
was generated by PCR with vaccinia virus WR DNA and the oligonucleotide
primers
5'-GGGGGGCCCATGGACTTCTTTAACAAGTTCTCACAG (the NcoI site is underlined and the initiation codon
is shown in boldface) and
5'-GGGGGGCTCGAGAGCGTGATTTTAATATCC (the
XhoI site is underlined). The PCR product was digested with
NcoI and XhoI and inserted into the plasmid pTM-1
(31), generating pTM/A5. The NcoI-XhoI
fragment encoding for the A5L open reading frame from pTM/A5 was
excised and used to replace the NcoI-XhoI
fragment containing the copy of
-galactosidase present in pT7lacZ
(1), generating pVOTE/A5. The nucleotide sequence of the
open reading frame corresponding to A5L in pVOTE/A5 was determined by
using a ABI PRISM Dye Terminator Cycle Sequencing kit (Perkin-Elmer) and shown to be identical to the nucleotide sequence of the A5 open
reading frame in the vaccinia virus WR genome.
The plasmid used to delete the endogenous copy of A5L was constructed
in three steps. First, an 834-bp fragment preceding the gene was
generated by PCR using vaccinia virus WR DNA and the oligonucleotide
primers 5'-GGGGGGGCATGCTAAGATTGGATATTAAAATCACGC and 5'-GGGGGGAAGCTTCTGGATTAGGCTATAGGTGTC
containing SphI and HindIII restriction
sites (underlined), respectively. The PCR product was ligated into an
intermediate vector by using the TA cloning kit (Invitrogen), excised
with SphI and HindIII, and inserted into
pGEM-3, generating pA5delR. Second, the neomycin resistance gene
(neo) was excised from pGEM-NEO (20) by using
SalI and BamHI and inserted into pA5delR,
generating pA5delR/neo. Finally, an 1,188-bp fragment derived from
the region following the A5 gene was generated by PCR using
oligonucleotide
5'-GGGGGGGAGCTCGAGCGTCGACTACAG AGAACG and 5'-GGGGGGGGATCCAAGGCTTTAAAATTGAATTGC containing
SacI and BamHI sites (underlined), respectively.
The PCR product was ligated into an intermediate vector by using the TA
cloning kit (Invitrogen), excised with SacI and
BamHI, and inserted into pA5delR/neo, generating
pA5del/neo.
Construction of recombinant viruses.
The vA5Li recombinant
virus was constructed in two steps. First, the intermediate virus
containing two copies of the A5L gene was generated by homologous
recombination between vT7lacOI (1) and pVOTE/A5.
Approximately 106 BSC-1 cells were infected with vT7lacOI
at a multiplicity of infection (MOI) of 0.05 PFU/cell for 2 h at
37°C, rinsed with Opti-Mem (Life Technologies), and transfected with
5 µg of pVOTE/A5 by using Lipofectamine (Life Technologies) as
suggested by the manufacturer. After 4 h, the volume was increased
fivefold with complete medium, and after 48 h, the cells were
harvested and the virus was released by three freeze-thaw cycles. The
vA5Lint was selected by five rounds of plaque purification in BSC-1
cells in the presence of mycophenolic acid, xanthine, and hypoxanthine (11) under an overlay of 0.5% methylcellulose (M-0387;
Sigma) in complete medium. Small virus stocks were prepared, and the recombinational changes were confirmed by PCR and Southern blotting. The structure of vA5Lint was also confirmed by infecting BSC-1 cells at
a low MOI. Upon infection, the double-crossover vA5Lint produced large
multinucleated cells typical of a hemagglutinin gene deletion phenotype.
The recombinant virus vA5Li, containing an inducible copy of A5L, was
generated by homologous recombination between vA5Lint
and pA5del/neo.
The procedure was the same as that described above
except that
selective pressure was maintained by incubation in
the presence of G418
(1 mg/ml; Life Technologies). Plaques were
identified by staining with
neutral red, and the genomic structure
was confirmed by PCR and
Southern blot
analysis.
One-step virus growth.
BSC-1 cells were infected with 1 PFU
of virus/cell for 1 h at 37°C. The incubations were continued
with IPTG where applicable, and cells were harvested at various times.
Virus was released by three freeze-thaw cycles and stored at
80°C.
Virus titers were determined by plaque assays (11) under
0.5% methylcellulose in complete medium in the presence of 25 µM IPTG.
Western blot analysis.
Proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Novex),
transferred to Protran (Schleicher & Schuell), and blocked with 5%
nonfat dry milk in phosphate-buffered saline. The filters were probed
with antibodies specific to vaccinia virus proteins (a gift of B. Moss)
and visualized by subsequent incubations with an anti-rabbit
immunoglobulin G conjugated with alkaline phosphatase and Western Blue
reagent (Promega).
SDS-PAGE analysis of [35S]methionine-labeled
polypeptides.
BSC-1 cells were infected at 5 PFU/cell in the
presence or absence of IPTG. At the indicated times after infection,
the cells were incubated with methionine-free medium for 15 min,
labeled for 30 min with 100 µCi of [35S]methionine/ml,
harvested in 1% SDS-50 mM Tris-HCl (pH 8.0), and incubated with PAGE
loading buffer prior to SDS-PAGE. After electrophoresis, the gels were
dried and visualized by exposure on Bio-Max (Kodak) film.
Analysis of viral DNA.
Monolayers were infected with 1 PFU
of vA5Lint or vA5Li/ml in the presence or absence of 50 µM IPTG.
After 24 h, the cells were harvested and resuspended in cell
suspension buffer (10 mM Tris HCl [pH 7.2], 20 mM NaCl, 50 mM EDTA)
at 107 cells/ml. An equal volume of 2% CleanCut agarose
(Bio-Rad), preincubated at 50°C, was added, and the suspension was
formed into 100-µl plugs. After solidification at 4°C, the plugs
were treated with proteinase K as previously described (29).
The equilibrated agarose plugs were treated by electrophoresis on a
Bio-Rad clamped homogeneous electric field DRII apparatus for 22 h
at 6 V/cm with a switching time of 70 s. Agarose gels were stained
with ethidium bromide.
Purification of virus.
Monolayers of BSC-1 cells were
infected at 1 PFU/cell with vA5Lint or vA5Li in the presence of 50 µM
IPTG where indicated. The cells were incubated at 37°C for 72 h
and harvested, and viral particles were purified as described for
vaccinia virus (10). The infecting stock for most
experiments was the pellet fraction obtained by centrifugation through
a 36% sucrose cushion. For electron microscopy, material banded in two
sequential 24 to 40% sucrose gradients was used.
Electron microscopy.
BSC-1 cells were infected with vA5Lint
or vA5Li at an MOI of 3 PFU/cell. After 24 h, the cells were fixed
in 2% glutaraldehyde in 0.1 M Na cacodylate (pH 7.4) buffer. Purified
viral particles were incubated with an equal volume of 4%
glutaraldehyde in 0.2 M Na cacodylate (pH 7.4) buffer and collected by
centrifugation at 14,000 × g in a microcentrifuge.
Samples were embedded in Embed-812 (Electron Microscopy Sciences, Fort
Washington, Pa.) as previously described (54). Ultrathin
sections of infected cells and virions were viewed with a Phillips
CM100 electron microscope.
 |
RESULTS |
Construction of a recombinant vaccinia virus with an inducible A5L
gene.
Attempts to eliminate the vaccinia virus WR A5L open reading
frame (corresponding to A4L in vaccinia virus Copenhagen) by the
insertion of color markers or antibiotic resistance genes were
unsuccessful (data not shown), implying that A5 is essential for viral
replication in BSC-1 cells. The inducible bacterial system for the
Escherichia coli lac repressor has been adapted for the
regulation of genes in vaccinia virus (14, 38, 56). Recently, an improved version of the system in which the expression of
both T7pol and a target gene behind a T7 promoter are controlled by
lacO has been described (52, 54). Constitutive
expression of the lacI repressor leads to stringent
inhibition of both the T7pol and target genes. Infections in the
presence of inducer IPTG result in the derepression of T7 RNA
polymerase, which transcribes the target gene.
The recombinant virus designed to regulate the expression of the A5L
gene was constructed in two steps, starting with the
parent virus
(vT7lacOI), which contains the
lacI and T7 RNA polymerase
genes. Initially, a second copy of the A5L gene was inserted by
homologous recombination between vT7lacOI and pVOTE/A5, a plasmid
with
a copy of A5L under the control of the T7 promoter containing
lacO sequences, the
E. coli gpt gene (for
mycophenolic acid selection),
and flanking sequences derived from A56R,
into the nonessential
A56R gene (hemagglutinin locus). The resulting
virus, vA5Lint,
contains two copies of the A5L gene, the endogenous
copy and an
inducible copy under the control of the T7 promoter. The
structure
of the viral genome was confirmed by Southern blot analysis
and
PCR (data not shown). Also, the vA5Lint was shown by Western blot
analysis to express higher levels of A5 than vT7lacOI or vaccinia
virus
WR when infections were performed in the presence of 50
µM IPTG (data
not shown). In the second step, the endogenous copy
of A5L in vA5Lint
was deleted by insertion of the drug resistance
gene
neo by
homologous recombination between vA5Lint and pA5del/neo,
a plasmid
containing the
neo gene (for selection) flanked by sequences
proximal to the A5L open reading frame. Recombinant viruses were
selected by plaque isolation in BSC-1 cells treated with G418
and,
after multiple rounds, individual plaques were selected and
expanded by
infecting BSC-1 cells. The genomes of candidate viruses
were then
analyzed by Southern blot analysis and PCR on isolated
DNA (data not
shown). A drug-resistant virus, containing only
the inducible copy of
vaccinia virus WR A5L, and with the genomic
structure outlined in Fig.
1, was isolated and designated vA5Li.

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 1.
Inducible expression of the A5L gene. Portions of the
genome for vA5Li are illustrated. DNA insertions have been made in the
vaccinia virus thymidine kinase (TK), the A5L, and the hemagglutinin
(A56R) genes. Abbreviations: P11 and P7.5, vaccinia virus promoters;
PT7 and T7 pol, a bacteriophage T7 promoter and the bacterial T7 RNA
polymerase gene, respectively; EMC, a cDNA copy of the untranslated
leader of encephalomyocarditis virus which provides cap-independent
translation; lacI and lacO, the E. coli
lac repressor gene and the lac operator, respectively;
neo and gpt, antibiotic selection genes.
|
|
Replication of mutant viruses.
Virus replication was measured
by plaque assay with one-step growth conditions in the presence or
absence of IPTG. Each virus was used to infect monolayers of BSC-1
cells at an MOI of 1 in the presence or absence of 50 µM IPTG,
harvested after 24 h, and analyzed by plaque assay on BSC-1 cells
(Fig. 2). The yield of virus was
independent of inducer for vT7lacOI and vA5Lint, whereas the yield of
vA5Li was directly dependent on the presence of IPTG. The rates of
growth for each virus were also compared (Fig.
3), and all viruses except vA5Li that
were incubated in the absence of IPTG grew at the same rate. Growth
profiles identical to those observed for vA5Lint and vT7lacOI were
observed for vaccinia virus WR infections (data not shown). Primary
infection of BSC-1 cells with vA5Li in the presence of IPTG produced
plaques which were indistinguishable in size and morphology from the
vaccinia virus wild type and vA5Lint, while infections of BSC-1 cells
with vA5Li in the absence of IPTG produced tiny pinpoint plaques. The
yield of infectious virus 24 h after infection from cells infected
with vA5Li was reproducibly about 100-fold lower than that from
infections with vA5Li performed in the presence of 50 µM IPTG. A
limited infection from the input vA5Li, especially at 48 h, may
result from the A5 protein present in the input virus stocks grown in the presence of IPTG or from a low level of expression by vA5Li, even
in the absence of IPTG.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 2.
Inducer dependence of virus production. Monolayers of
BSC-1 cells were infected with viruses vT7lacOI, vA5Lint, and vA5Li at
an MOI of 1 PFU per cell in the presence (+) or absence ( ) of 50 µM
IPTG. After 24 h, the monolayers were harvested, the virus was
released by three cycles of freezing-thawing, and BSC-1 monolayers were
infected in the presence of 25 µM IPTG, incubated for 4 days at
37°C, stained with crystal violet, and photographed.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Inducer-dependent formation of infectious virus. BSC-1
monolayers were infected with the viruses vT7lacOI, vA5Lint, or vA5Li
at an MOI of 1 PFU per cell in the presence (+) or absence ( ) of 50 µM IPTG. At various time points up to 48 h, the cells were
harvested and virus titers were determined by plaque assay on BSC-1
cells.
|
|
This T7 RNA polymerase inducible system was designed to scale the level
of expression of the target gene to the concentration
of IPTG. This
property allows one to express the target gene at
the optimum level, as
overexpression of the target gene is sometimes
deleterious to viral
growth (
5). The relationship between inducer
concentration
and vA5Li virus yield was determined by plaque assay
of infected cells
as illustrated in Fig.
4. In each
infection,
BSC-1 cells were infected at an MOI of 1 PFU/cell, harvested
after
24 h, and analyzed by plaque assay on BSC-1 cells. The yield
of
virus was directly proportional to IPTG concentration up to 50
µM.
The absolute number of plaques at 250 µM IPTG was approximately
half
that observed at 50 µM IPTG (Fig.
5).
The levels of expression
of A5L in cells infected with vA5Li at
different IPTG concentrations
were also compared by Western blot
analysis (Fig.
6). The accumulation
of A5
protein from cells infected with vA5Li was directly proportional
to the
concentration of IPTG. As expected, the production of A5
protein in
cells infected by vaccinia virus WR was insensitive
to IPTG
concentration. The amount of A5 protein synthesized in
vA5Li-infected
cells at approximately 10 µM IPTG was equivalent
to the amount
synthesized during an infection with WR. Upon overexposure
of the
Western blots, a low level of A5 (less than 10% of a WR
infection) was
noted in the absence of IPTG.

View larger version (84K):
[in this window]
[in a new window]
|
FIG. 4.
Inducer concentration and virus production. Monolayers
of BSC-1 cells were infected with virus vA5Li at an MOI of 1 PFU per
cell in the presence of 0, 5, 10, 25, 50, or 250 µM IPTG. After
24 h, the monolayers were harvested, the virus was released by
three cycles of freezing-thawing, and BSC-1 monolayers were infected in
the presence of 25 µM IPTG, incubated for 2 days at 37°C, stained
with crystal violet, and photographed.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 5.
Inducer dependence of virus yield. Monolayers of BSC-1
cells were infected with virus vA5Li at an MOI of 1 PFU per cell in the
presence of 0, 5, 10, 25, 50, or 250 µM IPTG. After 24 h, the
monolayers were harvested, the virus was released by three cycles of
freezing-thawing, and the titers were determined by plaque assay on
BSC-1 monolayers infected in the presence of 25 µM IPTG.
|
|

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 6.
Synthesis of A5L depends on IPTG concentration. BSC-1
cells were infected with either vA5Li at an MOI of 1 PFU/cell in the
presence of 0, 5, 10, 25, or 50 µM IPTG or vaccinia virus WR at an
MOI of 1 PFU/cell in the presence of 0 or 50 µM IPTG. After 24 h, the cells were harvested by scraping, concentrated by low-speed
centrifugation, and lysed in RIP lysis buffer (100 mM Tris HCl [pH
8.0], 100 mM NaCl, 0.5% Nonidet P-40). Samples were analyzed by
Western blotting by using a rabbit antibody against A5L supplied by
Bernard Moss followed by incubation with an anti-rabbit
antibody-alkaline phosphatase conjugate (Promega) and visualized by
using Western Blue Stabilized substrate for alkaline phosphatase
(Promega).
|
|
The highest level of vA5Li virus production occurred at an IPTG
concentration of 50 µM. At this inducer concentration, there
appeared
to be approximately 10 times the A5 normally found in
a vaccinia virus
WR infection. Since the protein coding sequence
for A5 was identical to
the sequence of WR, the optimal virus
production at the elevated level
of A5 reflects a less efficient
utilization of the protein, either
directly or by some posttranslational
process in the cells infected
with the recombinant virus. Similar
elevated levels of inducer gene
expression for optimum virus production
has been observed previously by
using the VOTE expression system
(
5,
19,
54). At the inducer
concentration of 250 µM IPTG,
even though a higher level of A5
production was observed (data
not shown), a decrease in vA5Li
production was noted (Fig.
5).
A decrease in virus yield at high
inducer concentrations has been
previously observed (
5,
19)
and attributed to a toxic effect
resulting from the overexpression of
the target
protein.
Synthesis of viral proteins.
When BSC-1 cells were infected
with vA5Li in the absence of A5 production, the yield of infectious
virus was greatly reduced. The influence of A5 on the general pattern
and timing of viral protein synthesis was investigated by SDS-PAGE of
infected cells pulse-labeled with [35S]methionine (Fig.
7). Vaccinia virus early proteins are
difficult to resolve from the background of host cell synthesis. At
late times after infection, virus-specific bands are clearly
discernible since host protein synthesis is inhibited. The pattern of
viral late protein expression was nearly identical in cells infected with vA5Li, irrespective of inducer concentration. The major difference was an additional band with an approximate molecular mass of 39 kDa
(most obvious at the 12-h time point), which corresponds to the
molecular mass of A5, in the presence of inducer. A few other minor
changes (an additional band between the 69- and 46-kDa markers in the
presence of inducer and an additional protein band between the 30- and
46-kDa markers in the absence of inducer) were also observed.
Therefore, the defect in replication of vA5Li was not due to a general
perturbation in protein synthesis.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 7.
Protein synthesis in cells infected with vaccinia virus
WR or vA5Li. BSC-1 cells were infected with vaccinia virus WR or vA5Li
at an MOI of 5 PFU per cell in the presence (+) or absence ( ) of 50 µM IPTG. At the indicated times after infection, the cells were
labeled for 30 min with [35S]methionine. Cell lysates
were analyzed by SDS-PAGE, and protein products were visualized by
exposure on Kodak Bio-Max film. U, uninfected.
|
|
Synthesis and processing of viral DNA.
Localization of A5
during the course of an infection demonstrated that the protein
colocalizes with the viral DNA, initially in the sites of viral DNA
replication and later becoming packaged in the mature infectious virion
(6). The synthesis and resolution of viral DNA from vA5Li
infections were measured by pulsed-field analysis of DNA isolated from
infected cells. Monolayers of BSC-1 cells were infected with vA5Lint or
vA5Li and incubated in the presence or absence of 50 µM IPTG, and the
DNA was analyzed 24 h postinfection (Fig.
8). The amount of DNA and distribution of full-length monomer genomes were the same in cells infected with either
virus irrespective of the presence or absence of inducer. The band
migrating at approximately 200 kbp was shown by Southern blotting to be
vaccinia virus DNA (data not shown). Also, telomere resolution occurred
in the presence or absence of inducer as determined by the appearance
of the 1.3-kbp resolved telomere fragment after BstEII
digestion (29) and Southern blot analysis (data not shown). Therefore, the absence of A5 has no effect on the synthesis and processing of vaccinia virus DNA.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 8.
Synthesis and processing of viral DNA. BSC-1 cells were
infected with vA5Lint or vA5Li at an MOI of 1 PFU/cell in the presence
(+) or absence ( ) of 50 µM IPTG. Total DNA was purified 48 h
after infection and resolved by pulsed-field gel electrophoresis. The
arrow corresponds to 200 kbp as determined by a multimeric lambda DNA
marker.
|
|
Morphogenesis of vA5Li.
The A5 protein was not expressed in
BSC-1 cells infected with vA5Li in the absence of IPTG. The lack of A5
did not influence the general details of protein expression or DNA
replication. A potential explanation for the defect in virus
replication is that the lack of A5 affects viral assembly or
morphogenesis. The constituents of infected cells were investigated by
electron microscopy. Electron microscopic images of cells infected with
vA5Li in the presence of IPTG (Fig. 9C)
contained representatives of all stages of viral morphogenesis, with a
majority of the observed structures being brick-shaped IMV particles.
In cells infected with vA5Li in the absence of IPTG, representative
structures of each stage of morphogenesis were also observed. However,
the most common structures detected were the spherical IV particles
(Fig. 9A and B). Some IV particles also contained electron-dense
nucleoids thought to be packaged DNA (13, 16). In addition,
we noted an increased frequency of aberrant IV structures (Fig. 9A) in which crescents and nascent IVs appeared to be enclosed by a second IV
membrane. However, these abnormal IVs represented a minority of the IVs
generated (Fig. 9B). Therefore, the electron microscopy data suggests
that repression of A5 synthesis leads to an accumulation of IVs blocked
in the normal progression to IMV.

View larger version (128K):
[in this window]
[in a new window]
|
FIG. 9.
Morphogenesis of mutant viruses. BSC-1 cells were
infected with vA5Li in the absence (A and B) or presence (C) of 50 µM
IPTG at an MOI of 3 PFU per cell. After 24 h, the cells were fixed
in glutaraldehyde and embedded in Epon, and ultrathin sections were
prepared for electron microscopy. nu, nucleoid.
|
|
Infectivity, composition, and morphology of purified
particles.
The accumulation of IV particles in cells infected with
vA5Li provides us with an opportunity to purify viral particles
predominantly at one stage of viral morphogenesis. Cells infected with
vA5Li in the presence (vA5Li+) or absence (vA5Li
) of IPTG were
harvested after 72 h, and viral particles were purified by sucrose
density gradient centrifugation. A cloudy band was observed in similar positions for vA5Li+ and vA5Li
. The infectivity of the particles, as
measured by plaque assay on BSC-1 cells, was compared by using matched
protein concentrations of WR, vA5Li+, and vA5Li
virion preparations.
The infectivity of vA5Li
, per its optical density at 280 nm
(OD280) was 7% of that of vA5Li+. The infectivity of the
vA5Li+ particles was 82%, essentially identical to the infectivity of
particles derived from WR.
The composition of the purified particles was determined by SDS-PAGE
and silver staining (Fig.
10). The
protein patterns of
vA5Li+ and vA5Li

were almost identical, with the
observed differences
consisting of a few additional high-molecular-mass
bands and an
absent band of approximately 39 kDa in vA5Li

. Also, a
more concentrated
97-kDa band appears in vA5Li

and may correspond to
uncleaved
p4a. The lower band probably corresponds to A5, as Western
blot
analysis of vA5Li

particles confirmed that A5 was greatly
reduced
in vA5Li

compared to vA5Li+ or WR virion particles (Fig.
10).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 10.
Protein content and Western blot analysis of purified
virus particles. Particles purified by sucrose gradient centrifugation
from BSC-1 cells infected with vA5Li in the presence (+) or absence
( ) of 50 µM IPTG or infected with wild-type vaccinia virus in the
absence of IPTG (WR) were adjusted to similar protein concentrations
and analyzed by SDS-PAGE and silver staining (Integrated Separation
Systems kit). Analogous protein samples were separated by SDS-PAGE, and
the proteins were transferred to Protran (Schleicher & Schuell) and
blocked with 5% nonfat dry milk in phosphate-buffered saline. The
filters were probed with rabbit antibodies directed against specific
vaccinia virus proteins (gift of B. Moss) and visualized by subsequent
incubations with an anti-rabbit immunoglobulin G conjugated with
alkaline phosphatase and Western Blue reagent (Promega).
|
|
The prevalence of specific viral proteins in vA5Li

and vA5Li+
particles was determined by Western blot analysis using antibodies
directed against specific viral proteins. Equivalent amounts of
protein, as determined by their OD
280, were separated by
PAGE,
transferred to membranes, and treated with antibodies directed
against the RNA polymerase-associated protein H4L, a subunit of
the
viral early transcription factor D6R, and core protein p4a,
or A10L
(Fig.
10). The only observed difference between vA5Li+
and vA5Li

,
other than A5L, was the higher percentage of uncleaved
precursor of
A10L (p4a) in the vA5Li

sample, indicative of incomplete
maturation.
The relative distribution of the two forms of A10L
was determined by
image analysis, and the higher-molecular-mass
band was shown to
correspond to 12% and 2% of the A10L in the
vA5Li

and vA5Li+
particles, respectively. The process of purification
appears to enrich
for mature virions, as the percentage of mature
particles in purified
preparations of vA5Li

(14 to 21%) was higher
than the percentage of
mature particles observed in infected cells
in the absence of IPTG
(less than 5%). In addition to the H4L
and D6R proteins illustrated in
Fig.
10, no differences in protein
concentrations were noted for the
A17L gene, a membrane protein,
A8R, a subunit of the viral early
transcription factor, and I7L,
an enzyme (data not
shown).
The particles were tested to determine if they contained viral DNA by
applying matched protein concentrations of WR, vA5Li+,
and vA5Li

to a
Nytran membrane, hybridizing the viral DNA with
fluorescein-labeled
viral DNA, and visualizing the hybridized
product with an
anti-fluorescein horseradish peroxidase antibody
and luminol (ECL kit).
All three samples hybridized equally well
to probe (data not shown),
demonstrating that all three types
of particles contained the same
amount of viral DNA. Therefore,
the loss of A5 expression does not
interfere with viral DNA
packaging.
The purified particles were sedimented, and thin sections were examined
by electron microscopy. The vA5Li+ particles were
primarily brick
shaped with clearly visible dumbbell-shaped cores,
similar in
appearance to WR. The vA5Li

preparation contained
some wild-type
particles but was composed mainly of irregular
roundish particles
lacking a clear dumbbell-shaped core structure
(Fig.
11). The irregular shapes of the
vA5Li

particles, in contrast
to the spherical shapes observed in the
infected cells, presumably
arose during purification or preparation for
microscopy.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 11.
Electron microscopy of purified virus particles.
Particles purified by sucrose gradient centrifugation from BSC-1 cells
infected with vA5Li in the presence (vA5Li+) or absence (vA5Li ) of 50 µM IPTG were collected by high-speed centrifugation, fixed in
glutaraldehyde, and embedded in Epon. Ultrathin sections were examined
by electron microscopy.
|
|
Although the protein composition of the vA5Li+ and vA5Li

viral
particles appears to be almost identical in the distribution
and
amounts of most viral proteins, the functional state of proteins
in the
viral particles was unknown. An infectious virion can be
activated in
vitro to transcribe viral genes (
23,
33). The
ability of the
vA5Li+ and vA5Li

particles to incorporate [

-
32P]UTP
was measured as a function of protein concentration (
5)
by
using a series of protein concentrations, and vA5Li

particles
were
shown to elicit about 75% of the activity determined for
vA5Li+
particles. Also, virion extracts were prepared (
17) from
vA5Li+ and vA5Li

particles and assayed for virion nuclease activity
(
28). Both types of particles were shown to possess
equivalent
levels of nuclease activity (data not
shown).
 |
DISCUSSION |
We used a genetic approach to discern the role of A5 in a vaccinia
virus infection by the construction and characterization of vA5Li, a
vaccinia virus recombinant with an inducible A5 gene. The correct
genomic structure of the recombinant was confirmed by Southern blotting
and PCR. The expression of A5 in vA5Li was demonstrated to be dependent
on and directly proportional to the concentration of IPTG inducer, with
maximum yields of virus realized at concentrations of 50 µM IPTG. The
residual low yield of infectious virus in the absence of inducer may
result from the inefficient production of virus at the low levels of
basal A5 expression in the absence of IPTG or reflect an inherent low
infectivity of virions lacking A5. Also, some virus may be produced by
using the residual A5 carried into the infected cell by the virus grown in the presence of IPTG.
In an attempt to determine the stage of viral replication affected by
the absence of A5, metabolic steps involved in virion replication were
investigated by analysis of viral protein expression as well as DNA
replication and resolution from infections of vA5Li in the presence or
absence of inducer. The overall pattern of protein expression was the
same for infections performed in the presence or absence of IPTG. The
viral DNA was replicated and completely resolved in the absence of
inducer. These results suggest that the role of A5 in viral replication
is not manifested in viral transcription or replication. However, since
A5 is a virion component and stocks of vA5Li are grown in the presence
of inducer, we cannot rule out a role for A5 in early gene expression.
Electron-microscopic analysis of viral morphogenesis in cells infected
with vA5Li in the presence of IPTG demonstrated the presence of all of
the usual stages of morphogenesis, including the mature, brick-shaped
infectious virions. Cells infected with vA5Li in the absence of inducer
also contained structures representative of all stages of vaccinia
morphogenesis. However, only a minority of the structures observed were
the mature infectious brick-shaped particles; most of the structures
were spherical IVs. Nucleoids were observed in some of the immature
particles, implying that DNA packaging is unaffected by the lack of A5.
Interestingly, we also observed what appeared to be an accumulation of
aberrant immature forms in which crescent structures of various degrees of development were enclosed within a normally sized IV. In some cases,
it appeared as if a virion had acquired two complete membranes. Although the number of aberrant forms may well be underrepresented due
to the plane of sectioning, it appeared that the majority of the IVs
were normal. The accumulation of these abnormal structures may be
indicative of a direct role of the A5 protein in the appropriate formation and development of the crescent membranes and IVs but may
also be the result of a delay in or decreased efficiency of this stage
of morphogenesis due to the role of A5 protein in another process.
Further study is required to address this point.
The particles arising from vA5Li infections were purified 72 h
postinfection by banding in sucrose gradients. The protein and DNA
components of the vA5Li+ and vA5Li
particles were nearly identical.
The only obvious differences detected in the protein pattern were the
amount of A5L and the form of p4a present. Specific protein
constituents assayed by Western blotting demonstrated that the
structural proteins A17L and I7L, the two subunits of the early
transcription factor, A8R and D6R, and the RNA polymerase component H4L
were found in equal amounts in vA5Li+ and vA5Li
preparations. The
vA5Li
particles contained more of the unprocessed form of A10L (p4a),
implying that inhibition of A5L gene expression delays or partially
blocks proteolytic processing of core protein precursors.
The infectivity of the vA5Li
particles was consistently lower than
for vA5Li+, as measured by PFU on BSC-1 cells. The in vitro
transcriptional activity of vA5Li
particles was consistently about
75% of the level obtained with a protein equivalent of vA5Li+. Since
the particles contain a full complement of viral transcriptional components, the difference in infectivity may be a reflection of the
relative integrity of the particles. Partially purified preparations of
vA5Li
left in sucrose were observed to become viscous and, in
contrast to vA5Li+, did not give a discrete band upon centrifugation in
sucrose gradients. The fragile nature of the vA5Li
particles may lead
to their more frequent rupture, explaining the irregular shape observed
by electron microscopy and the lower level of nonspecific
transcriptional activity. The data does not unambiguously demonstrate
whether the lowered infectivity of vA5Li
results from an impaired
ability to infect the cell or from a more fragile viral particle which
is less likely to survive the purification process intact. The level of
infectivity for each preparation of vA5Li
was proportional to the
percentage of mature brick-shaped particles. The percentage of
brick-shaped mature viral particles in different preparations of
vA5Li
ranged from approximately 14 to 21% and was directly
proportional to the amount of A5 detected by Western blotting.
Preparations of vA5Li+ consistently contained about 80% brick-shaped
mature viral particles.
The progression from IV to IMV particle uses site-dependent
protein-protein, lipid-protein, and nucleic acid-protein interactions to generate a sequence of specific structures. The core proteins form
the structural internal lattice of the infectious virion, and the loss
of any of these proteins may lead to aberrant intermediate structures
which are unable to progress to the subsequent stage on the pathway to
infectious IMV. Conditional lethal viruses have been useful in
identifying several viral core proteins important for vaccinia virus
morphogenesis. Conditional repression of functional A5L (this study),
F18R (p11) (57), the I7L gene product (13, 22),
or membrane-bound core protein L1R (35) led to the
accumulation of IV particles.
Other proteins which have not yet been identified as structural core
proteins affect the transition from IV to IMV. The conditional repression of the two components of the viral early transcription factor, A8R and D6R, leads to the accumulation of IV particles (19, 20). These proteins are present in the viral core and are relatively abundant but do not have a previously documented structural role. Also, the conditional repression of the A32L protein
resulted in the accumulation of IV particles (5) which did
not contain DNA. The location or presence of A32L, which is not an
abundant protein, is unknown.
Previous studies of the p39 protein, or A5L, are consistent with its
apparent role in virion morphogenesis. Biochemical studies indicated
that the protein was present in the viral factories and the central
region of IV particles (6). During the transition from IV to
IMV, the location of A5 changes and it becomes localized between two
membranes proximal to the core, possibly forming the spikes found on
the outside of the viral core (6). This location is
consistent with a role for A5 in maturation at a late step in IMV formation.
The requirement for A5 in poxvirus replication is underscored by the
retention of its homologous open reading frame in the widely diverged
poxviruses molluscum contagiosum (43) and modified virus
ankara (MVA) (2). Compared to the nucleotide sequence for
vaccinia virus Copenhagen, the analogue to the vaccinia virus WR A5L
open reading frame is missing 27 nucleotides in MVA, leading to an
internal deletion of nine amino acids (2). Infections of MVA
in non- and semipermissive cell lines produce a nonpropagating virus
blocked in morphogenesis at the accumulation of IV particles (45). The role for A5 in vaccinia virus replication
described in this article suggests that the altered protein in MVA may
contribute to the phenotype of restricted host range in morphogenesis.
The viral gene A5L is essential for virus growth and is synthesized
late in the viral life cycle. The association of A5L with the site of
viral DNA replication and processing and its copurification with the
viral nicking-closing enzyme led to our initial interest in the role of
this protein in vaccinia virus infection. Using the viral construct
vA5Li, which contains an inducible copy of A5L, we have clearly
demonstrated that A5L does not encode a protein with nuclease activity.
The protein is required for the progression of IV to infectious IMV
particles. This data is consistent with the time course of synthesis
and location of the protein during infection.
 |
ACKNOWLEDGMENTS |
We thank Jerry Weir, Miles Carroll, and Xiaolei Hu for helpful
discussions and Bernie Moss and Norman Cooper for reagents.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Viral Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, HFM-457, 1401 Rockville Pike, Rockville, MD
20852-1448. Phone: (301) 827-2934. Fax: (301) 480-1597. E-mail: merchlinsky{at}cber.fda.gov.
 |
REFERENCES |
| 1.
|
Alexander, W. A.,
B. Moss, and T. R. Fuerst.
1992.
Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor.
J. Virol.
66:2934-2942[Abstract/Free Full Text].
|
| 2.
|
Antoine, G.,
F. Scheiflinger,
F. Dorner, and F. G. Falkner.
1998.
The complete genomic sequence of the modified vaccinia ankara strain: comparison with other orthopoxviruses.
Virology
244:365-396[Medline].
|
| 3.
|
Blasco, R., and B. Moss.
1991.
Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein.
J. Virol.
65:5910-5920[Abstract/Free Full Text].
|
| 4.
|
Cairns, J.
1960.
The initiation of vaccinia infection.
Virology
11:603-623[Medline].
|
| 5.
|
Cassetti, M. C.,
M. Merchlinsky,
E. J. Wolffe,
A. S. Weisberg, and B. Moss.
1998.
DNA packaging mutant: repression of the vaccinia virus A32 gene results in noninfectious, DNA-deficient, spherical, enveloped particles.
J. Virol.
72:5769-5780[Abstract/Free Full Text].
|
| 6.
|
Cudmore, S.,
R. Blasco,
R. Vincentelli,
M. Esteban,
B. Sodeik,
G. Griffiths, and J. K. Locker.
1996.
A vaccinia virus core protein, p39, is membrane associated.
J. Virol.
70:6909-6921[Abstract/Free Full Text].
|
| 7.
|
Dales, S., and L. Siminovitch.
1961.
The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy.
J. Biophys. Biochem. Cytol.
10:475-498.
[Abstract/Free Full Text] |
| 8.
|
Demkowicz, W. E.,
J.-S. Maa, and M. Esteban.
1992.
Identification and characterization of vaccinia genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans.
J. Virol.
66:386-398[Abstract/Free Full Text].
|
| 9.
|
Duncan, S. A., and G. L. Smith.
1992.
Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress.
J. Virol.
66:1610-1621[Abstract/Free Full Text].
|
| 10.
|
Earl, P. L.,
N. Cooper, and B. Moss.
1991.
Preparation of cell cultures and vaccinia virus stocks, p. 16.16.1-16.16.7.
In
F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Greene Publishing Associates and Wiley Interscience, New York, N.Y.
|
| 11.
|
Earl, P. L., and B. Moss.
1991.
Generation of recombinant vaccinia viruses, p. 16.17.1-16.17.16.
In
F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Greene Publishing Associates and Wiley Interscience, New York, N.Y.
|
| 12.
|
Engelstad, M., and G. L. Smith.
1993.
The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.
Virology
194:627-637[Medline].
|
| 13.
|
Ericsson, M.,
S. Cudmore,
S. Shuman,
R. C. Condit,
G. Griffiths, and J. K. Locker.
1995.
Characterization of ts16, a temperature-sensitive mutant of vaccinia virus.
J. Virol.
69:7072-7086[Abstract].
|
| 14.
|
Fuerst, T. R.,
M. P. Fernandez, and B. Moss.
1989.
Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector.
Proc. Natl. Acad. Sci. USA
86:2549-2553[Abstract/Free Full Text].
|
| 15.
|
Goebel, S. J.,
G. P. Johnson,
M. E. Perkus,
S. W. Davis,
J. P. Winslow, and E. Paoletti.
1990.
The complete DNA sequence of vaccinia virus.
Virology
179:247-266[Medline].
|
| 16.
|
Grimley, P. M.,
E. N. Rosenblum,
S. J. Mims, and B. Moss.
1970.
Interruption by rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes.
J. Virol.
6:519-533[Abstract/Free Full Text].
|
| 17.
|
Gross, C. H., and S. Shuman.
1996.
Vaccinia virions lacking the RNA helicase nucleoside triphosphate phosphohydrolase II are defective in early transcription.
J. Virol.
70:8549-8557[Abstract].
|
| 18.
|
Harford, C. G.,
A. Hamlin, and E. Riders.
1966.
Electron microscopic autoradiography of DNA synthesis in cells infected with vaccinia virus.
Exp. Cell Res.
42:50-57[Medline].
|
| 19.
|
Hu, X.,
L. J. Carroll,
E. J. Wolffe, and B. Moss.
1996.
De novo synthesis of the early transcription factor 70-kilodalton subunit is required for morphogenesis of vaccinia virions.
J. Virol.
70:7669-7677[Abstract].
|
| 20.
|
Hu, X.,
E. J. Wolffe,
A. S. Weisberg,
L. J. Carroll, and B. Moss.
1998.
Repression of the A8L gene, encoding the early transcription factor 82-kilodalton subunit, inhibits morphogenesis of vaccinia virions.
J. Virol.
72:104-112[Abstract/Free Full Text].
|
| 21.
|
Joklik, W. K., and Y. Becker.
1964.
The replication and coating of vaccinia DNA.
J. Mol. Biol.
10:452-474.
|
| 22.
|
Kane, E. M., and S. Shuman.
1993.
Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the I7 gene that encodes a virion component.
J. Virol.
67:2689-2698[Abstract/Free Full Text].
|
| 23.
|
Kates, J. R., and B. R. McAuslan.
1967.
Poxvirus DNA-dependent RNA polymerase.
Proc. Natl. Acad. Sci. USA
58:134-141[Free Full Text].
|
| 24.
|
Katz, E., and B. Moss.
1970.
Formation of a vaccinia virus structural polypeptide from a high molecular weight precursor: inhibition by rifampicin.
Proc. Natl. Acad. Sci. USA
66:677-684[Abstract/Free Full Text].
|
| 25.
|
Katz, E., and B. Moss.
1970.
Vaccinia virus structural polypeptide derived from a high-molecular-weight precursor: formation and integration into virus particles.
J. Virol.
6:717-726[Abstract/Free Full Text].
|
| 26.
|
Lakritz, N.,
P. D. Foglesong,
M. Reddy,
S. Baum,
J. Hurwitz, and W. R. Bauer.
1985.
A vaccinia DNase preparation which cross-links superhelical DNA.
J. Virol.
53:935-943[Abstract/Free Full Text].
|
| 27.
|
Maa, J.-S., and M. Esteban.
1987.
Structural and functional studies of a 39,000-Mr immunodominant protein of vaccinia virus.
J. Virol.
61:3910-3919[Abstract/Free Full Text].
|
| 28.
|
Merchlinsky, M.,
C. F. Garon, and B. Moss.
1988.
Molecular cloning and sequence of the concatemer junction from vaccinia virus replicative DNA. Viral nuclease cleavage sites in cruciform structures.
J. Mol. Biol.
199:399-413[Medline].
|
| 29.
|
Merchlinsky, M., and B. Moss.
1989.
Resolution of vaccinia virus DNA concatemer junctions requires late gene expression.
J. Virol.
63:1595-1603[Abstract/Free Full Text].
|
| 29a.
| Merchlinsky, M. Unpublished results.
|
| 30.
|
Moss, B.
1996.
Poxviridae: the viruses and their replication, p. 2637-2672.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
|
| 31.
|
Moss, B.,
O. Elroy-Stein,
T. Mizukami,
W. A. Alexander, and T. R. Fuerst.
1990.
New mammalian expression vectors.
Nature (London)
348:91[Medline].
|
| 32.
|
Moss, B., and E. N. Rosenblum.
1973.
Protein cleavage and poxvirus morphogenesis: tryptic peptide analysis of core precursors accumulated by blocking assembly with rifampicin.
J. Mol. Biol.
81:267-269[Medline].
|
| 33.
|
Munyon, W. E.,
E. Paoletti, and J. T. Grace, Jr.
1967.
RNA polymerase activity in purified infectious vaccinia virus.
Proc. Natl. Acad. Sci. USA
58:2280-2288[Free Full Text].
|
| 34.
|
Parkinson, J. E., and G. L. Smith.
1994.
Vaccinia virus gene A36R encodes a Mr 43-50 K protein on the surface of extracellular enveloped virus.
Virology
204:376-390[Medline].
|
| 35.
|
Ravanello, M. P., and D. E. Hruby.
1994.
Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly.
J. Virol.
68:6401-6410[Abstract/Free Full Text].
|
| 36.
|
Rodriguez, D.,
M. Esteban, and J. R. Rodriguez.
1995.
Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis.
J. Virol.
69:4640-4648[Abstract].
|
| 37.
|
Rodriguez, D.,
C. Risco,
J. R. Rodriguez, and M. Esteban.
1996.
Inducible expression of the vaccinia virus A17L gene provides a synchronized system to monitor sorting of viral proteins during morphogenesis.
J. Virol.
70:7641-7653[Abstract].
|
| 38.
|
Rodriguez, J. F., and G. L. Smith.
1990.
IPTG-dependent vaccinia virus: identification of a virus protein enabling virion envelopment by Golgi membrane and egress.
Nucleic Acids Res.
18:5347-5351[Abstract/Free Full Text].
|
| 39.
|
Roper, R. L.,
L. G. Payne, and B. Moss.
1996.
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene.
J. Virol.
70:3753-3762[Abstract].
|
| 40.
|
Rosemond-Hornbeak, H., and B. Moss.
1974.
Single-strand deoxyribonucleic acid-specific nuclease from vaccinia virus. Endonucleolytic and exonucleolytic activities.
J. Biol. Chem.
249:3292-3296[Abstract/Free Full Text].
|
| 41.
|
Rosemond-Hornbeak, H.,
E. Paoletti, and B. Moss.
1974.
Single-strand deoxyribonucleic acid-specific nuclease from vaccinia virus. Purification and characterization.
J. Biol. Chem.
249:3287-3291[Abstract/Free Full Text].
|
| 42.
|
Schmutz, C.,
L. G. Payne,
J. Gubser, and R. Wittek.
1991.
A mutation in the gene encoding the vaccinia virus 37,000-Mr protein confers resistance to an inhibitor of virus envelopment and release.
J. Virol.
65:3435-3442[Abstract/Free Full Text].
|
| 43.
|
Senkevich, T. G.,
J. J. Bugert,
J. R. Sisler,
E. V. Koonin,
G. Darai, and B. Moss.
1996.
Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes.
Science
273:813-816[Abstract].
|
| 44.
|
Silver, M., and S. Dales.
1982.
Biogenesis of vaccinia: interrelationship between posttranslational cleavage, virus assembly, and maturation.
Virology
117:341-356[Medline].
|
| 45.
|
Sutter, G., and B. Moss.
1992.
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Proc. Natl. Acad. Sci. USA
89:10847-10851[Abstract/Free Full Text].
|
| 46.
|
Tartaglia, J., and E. Paoletti.
1985.
Physical mapping and DNA sequence analysis of the rifampin resistance locus in vaccinia virus.
Virology
147:394-404[Medline].
|
| 47.
|
Traktman, P.,
A. Caligiuri,
S. A. Jesty,
K. Liu, and K. Sankar.
1995.
Temperature-sensitive mutants with lesions in the vaccinia virus F10 kinase undergo arrest at the earliest stage of virion morphogenesis.
J. Virol.
69:6581-6587[Abstract].
|
| 48.
|
VanSlyke, J. K.,
C. A. Franke, and D. E. Hruby.
1991.
Proteolytic maturation of vaccinia virus core proteins: identification of a conserved motif at the N termini of the 4b and 25K virion proteins.
J. Gen. Virol.
72:411-416[Abstract/Free Full Text].
|
| 49.
|
VanSlyke, J. K.,
P. Lee,
E. M. Wilson, and D. E. Hruby.
1993.
Isolation and analysis of vaccinia virus previrions.
Virus Genes
7:311-324[Medline].
|
| 50.
|
VanSlyke, J. K.,
S. S. Whitehead,
E. M. Wilson, and D. E. Hruby.
1991.
The multistep proteolytic maturation pathway utilized by vaccinia virus p4a protein: a degenerate conserved cleavage motif within core proteins.
Virology
183:467-478[Medline].
|
| 51.
|
Wang, S., and S. Shuman.
1995.
Vaccinia virus morphogenesis is blocked by temperature-sensitive mutations in the F10 gene, which encodes protein kinase 2.
J. Virol.
69:6376-6388[Abstract].
|
| 52.
|
Ward, G. A.,
C. K. Stover,
B. Moss, and T. R. Fuerst.
1995.
Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.
Proc. Natl. Acad. Sci. USA
92:6773-6777[Abstract/Free Full Text].
|
| 53.
|
Wolffe, E. J.,
S. N. Isaacs, and B. Moss.
1993.
Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination.
J. Virol.
67:4732-4741[Abstract/Free Full Text].
|
| 54.
|
Wolffe, E. J.,
D. M. Moore,
P. J. Peters, and B. Moss.
1996.
Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis.
J. Virol.
70:2797-2808[Abstract].
|
| 55.
|
Zhang, Y., and B. Moss.
1992.
Immature viral envelope formation is interrupted at the same stage by lac operator-mediated repression of the vaccinia virus D13L gene and by the drug rifampicin.
Virology
187:643-653[Medline].
|
| 56.
|
Zhang, Y., and B. Moss.
1991.
Inducer-dependent conditional-lethal mutant animal viruses.
Proc. Natl. Acad. Sci. USA
88:1511-1515[Abstract/Free Full Text].
|
| 57.
|
Zhang, Y., and B. Moss.
1991.
Vaccinia virus morphogenesis is interrupted when expression of the gene encoding an 11-kilodalton phosphorylated protein is prevented by the Escherichia coli lac repressor.
J. Virol.
65:6101-6110[Abstract/Free Full Text].
|
Journal of Virology, June 1999, p. 4590-4599, Vol. 73, No. 6
0022-538X/99/$04.00+0
This article has been cited by other articles:
-
Jesus, D. M., Costa, L. T., Goncalves, D. L., Achete, C. A., Attias, M., Moussatche, N., Damaso, C. R.
(2009). Cidofovir Inhibits Genome Encapsidation and Affects Morphogenesis during the Replication of Vaccinia Virus. J. Virol.
83: 11477-11490
[Abstract]
[Full Text]
-
Adamo, J. E., Meseda, C. A., Weir, J. P., Merchlinsky, M. J.
(2009). Smallpox vaccines induce antibodies to the immunomodulatory, secreted vaccinia virus complement control protein. J. Gen. Virol.
90: 2604-2608
[Abstract]
[Full Text]
-
Garcia, A. D., Meseda, C. A., Mayer, A. E., Kumar, A., Merchlinsky, M., Weir, J. P.
(2007). Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines. CVI
14: 1032-1044
[Abstract]
[Full Text]
-
Delhon, G., Tulman, E. R., Afonso, C. L., Lu, Z., de la Concha-Bermejillo, A., Lehmkuhl, H. D., Piccone, M. E., Kutish, G. F., Rock, D. L.
(2004). Genomes of the Parapoxviruses Orf Virus and Bovine Papular Stomatitis Virus. J. Virol.
78: 168-177
[Abstract]
[Full Text]
-
Carter, G. C., Rodger, G., Murphy, B. J., Law, M., Krauss, O., Hollinshead, M., Smith, G. L.
(2003). Vaccinia virus cores are transported on microtubules. J. Gen. Virol.
84: 2443-2458
[Abstract]
[Full Text]
-
Chiu, W.-L., Chang, W.
(2002). Vaccinia Virus J1R Protein: a Viral Membrane Protein That Is Essential for Virion Morphogenesis. J. Virol.
76: 9575-9587
[Abstract]
[Full Text]
-
Risco, C., Rodriguez, J. R., Lopez-Iglesias, C., Carrascosa, J. L., Esteban, M., Rodriguez, D.
(2002). Endoplasmic Reticulum-Golgi Intermediate Compartment Membranes and Vimentin Filaments Participate in Vaccinia Virus Assembly. J. Virol.
76: 1839-1855
[Abstract]
[Full Text]
-
Szajner, P., Weisberg, A. S., Wolffe, E. J., Moss, B.
(2001). Vaccinia Virus A30L Protein Is Required for Association of Viral Membranes with Dense Viroplasm To Form Immature Virions. J. Virol.
75: 5752-5761
[Abstract]
[Full Text]
-
Heljasvaara, R., Rodriguez, D., Risco, C., Carrascosa, J. L., Esteban, M., Rodriguez, J. R.
(2001). The Major Core Protein P4a (A10L Gene) of Vaccinia Virus Is Essential for Correct Assembly of Viral DNA into the Nucleoprotein Complex To Form Immature Viral Particles. J. Virol.
75: 5778-5795
[Abstract]
[Full Text]
-
Yeh, W. W., Moss, B., Wolffe, E. J.
(2000). The Vaccinia Virus A9L Gene Encodes a Membrane Protein Required for an Early Step in Virion Morphogenesis. J. Virol.
74: 9701-9711
[Abstract]
[Full Text]
-
Pedersen, K., Snijder, E. J., Schleich, S., Roos, N., Griffiths, G., Locker, J. K.
(2000). Characterization of Vaccinia Virus Intracellular Cores: Implications for Viral Uncoating and Core Structure. J. Virol.
74: 3525-3536
[Abstract]
[Full Text]
-
Traktman, P., Liu, K., DeMasi, J., Rollins, R., Jesty, S., Unger, B.
(2000). Elucidating the Essential Role of the A14 Phosphoprotein in Vaccinia Virus Morphogenesis: Construction and Characterization of a Tetracycline-Inducible Recombinant. J. Virol.
74: 3682-3695
[Abstract]
[Full Text]
-
DeMasi, J., Traktman, P.
(2000). Clustered Charge-to-Alanine Mutagenesis of the Vaccinia Virus H5 Gene: Isolation of a Dominant, Temperature-Sensitive Mutant with a Profound Defect in Morphogenesis. J. Virol.
74: 2393-2405
[Abstract]
[Full Text]